Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, and obesity drugs.
Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (NYSE:LLY) shares sold off on Tuesday after the Indiana-based pharma giant's Q4 and 2024 preliminary sales results for its obesity therapy tirzepatide fell short of Street forecasts. Novo Nordisk (NVO),
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
JD Supra4h
Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors
Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...
Has Eli Lilly Stock Peaked?
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion ...
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly & Co (LLY) Gets a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...